NIAMS Skin Biology and Diseases Resource-based Center (P30 - Clinical Trial Not Allowed)
ID: 359152Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359152
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "NIAMS Skin Biology and Diseases Resource-based Center (P30 - Clinical Trial Not Allowed)" aimed at supporting research infrastructure for skin diseases. This initiative seeks to establish resource-based centers that will provide essential facilities, services, and resources to enhance the efficiency and effectiveness of research conducted by groups of investigators in the field of skin diseases. The overall goal is to accelerate and enrich ongoing basic, translational, and clinical research aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). While applications are not currently being solicited, interested small businesses are encouraged to prepare collaborative proposals in anticipation of the estimated synopsis posting on September 4, 2025, with a closing date of November 3, 2025, and an expected award date of July 1, 2026. For further inquiries, potential applicants may contact Dr. Mary Garcia-Cazarin at mary.garcia-cazarin@nih.gov or by phone at 301-451-2937.

    Point(s) of Contact
    Mary Garcia-Cazarin, Ph.D. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    (301) 451-2937
    mary.garcia-cazarin@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Resource-based Centers for Rheumatic Diseases Research
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce a funding opportunity for Resource-based Centers for Rheumatic Diseases Research, aimed at enhancing research infrastructure for rheumatic diseases. This initiative will support small businesses in providing shared facilities, services, and resources to facilitate collaborative research efforts among investigators in this field. The goal is to accelerate and enrich ongoing basic, translational, and clinical research aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). While applications are not currently being solicited, interested parties are encouraged to develop collaborations and project proposals in anticipation of the upcoming Notice of Funding Opportunity (NOFO), with an estimated synopsis posting date of September 3, 2025, and a closing date of November 3, 2025. For further inquiries, potential applicants can contact Dr. Mary Garcia-Cazarin at mary.garcia-cazarin@nih.gov or by phone at 301-451-2937.
    Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Core Centers for Clinical Research (CCCR)" aimed at advancing methodological sciences in clinical research related to musculoskeletal, rheumatic, and skin diseases. This initiative seeks to establish centers that will focus on the prevention, diagnosis, and treatment of these conditions, emphasizing the development of novel methods and metrics while ensuring community representation throughout the research process. Eligible applicants include small businesses, with no cost-sharing or matching requirements, and the estimated project start date is set for July 1, 2027. Interested parties can reach out to Dr. Melissa C. Green Parker at melissa.greenparker@nih.gov or by phone at 240-755-3031 for further information, with the application period expected to close on September 25, 2026.
    Resource-based Centers for Bone, Muscle and Orthopaedic Research
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce a funding opportunity for Resource-based Centers focused on Bone, Muscle, and Orthopaedic Research. This initiative aims to establish centers that will provide essential research infrastructure, shared facilities, and resources to support investigators in conducting efficient and effective research projects in these critical areas. The goal is to enhance ongoing basic, translational, and clinical research aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). While applications are not currently being solicited, potential applicants are encouraged to develop collaborations and project proposals in anticipation of the funding announcement, which is expected to be published in September 2025. Interested parties can reach out to Dr. Mary Garcia-Cazarin at mary.garcia-cazarin@nih.gov or by phone at 301-451-2937 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that align with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), utilizing well-characterized patient cohorts, infrastructure, data, and biological samples from parent studies. With an estimated total program funding of $2 million and an expected four awards, interested small businesses are encouraged to collaborate and develop responsive projects. Key deadlines include an estimated synopsis post date of February 4, 2026, a close date of April 6, 2026, and an anticipated award date of December 4, 2026. For further inquiries, applicants can contact Heiyoung Park, Ph.D., at Heiyoung.Park@nih.gov or by phone at 301-827-5992.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)," aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that utilize well-characterized patient cohorts, infrastructure, data, and biological samples, while aligning with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). With an estimated total program funding of $600,000 and the expectation of awarding two grants, potential applicants are advised to begin developing collaborations and project proposals in advance of the official solicitation, which is expected to be published in early 2026. For further inquiries, interested parties may contact Dr. Heiyoung Park at Heiyoung.Park@nih.gov or by phone at 301-594-5032.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to support the late-stage translation of biomedical and behavioral research results related to arthritis, musculoskeletal, and skin diseases into marketable products. This Small Business Innovation Research (SBIR) grant (PAR-23-032) aims to foster collaboration between academic/non-profit labs and small business concerns (SBCs) to advance diagnostics, treatments, and prevention tools, while specifically excluding clinical trials. The initiative is crucial for bridging laboratory discoveries with real-world applications, ultimately enhancing public health outcomes through medical innovations. Interested applicants can seek funding up to $350,000, with ongoing application cycles from January 2024 to September 2025, and should direct inquiries to grantsinfo@nih.gov for further information.
    Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Promoting a Basic Understanding of Chemical Threats to Skin," aimed at small businesses interested in researching the pathological mechanisms of skin injuries caused by toxic chemicals. The initiative seeks to elucidate the commonalities in the mechanisms of skin injuries from various vesicants, such as sulfur mustard and Lewisite, with the goal of identifying shared therapeutic targets and developing broad-spectrum medical countermeasures for mass casualty events. The estimated total program funding is $2,500,000, with approximately five awards expected, and interested applicants are encouraged to collaborate and prepare their proposals ahead of the anticipated application period, which is expected to open in early 2026. For further inquiries, potential applicants can contact Dr. Peter J. Koch at Peter.Koch@NIH.gov or by phone at 240-987-8325.